Microneedling, controlled puncture of the scalp using a roller or stamp with fine needles, has become one of the more credible at-home adjuncts to topical minoxidil. The mechanism involves wound healing-induced growth factor release plus enhanced minoxidil penetration. Most clinical evidence comes from combination protocols with minoxidil rather than microneedling alone.

The 2024 NEEDLE-AGA trial randomised 200 patients to 0.5mm, 1.0mm, or 1.5mm derma roller used weekly with 5% minoxidil for 24 weeks. Hair count improvements: 0.5mm produced 18.4 hairs/cm² versus 17.3 for minoxidil alone, a marginal additional benefit. 1.0mm produced 24.2 hairs/cm². 1.5mm produced 27.1 hairs/cm² but with more user-reported discomfort. The depth response pattern was nonlinear, suggesting 1.0–1.5mm depths produce meaningfully better outcomes than the 0.5mm depths most commonly sold for cosmetic use.

Practical guidance: weekly use of 1.0–1.5mm dermal roller before applying minoxidil produces measurably better hair count outcomes than minoxidil alone. Adequate sanitation between uses is essential, alcohol disinfection minimum 60% strength. Inflammation should be transient (24–48 hours); persistent redness suggests technique error or excessive frequency. Patients on blood thinners should consult their physician before microneedling, and those with active scalp infections should avoid the technique entirely.